FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Clinical trials for FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Pill vs. IV drip: major trial tests easier treatment for returning ovarian cancer
Disease control OngoingThis large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat ovarian cancer
Disease control OngoingThis study is testing whether a combination of two oral drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemoth…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists weaponize measles virus to fight ovarian cancer
Disease control OngoingThis study is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Doctors are using a specially engineered measles virus, which is carried directly to the cancer by the patient's own fat-derived stem cells, …
Matched conditions: FALLOPIAN TUBE UNDIFFERENTIATED CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC